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Micro-computed tomography (micro-CT) facilitates the visualization and quantification of contrast-enhancedmicrovessels within
intact tissue specimens, but conventional preclinical vascular contrast agents may be inadequate near dense tissue (such as bone).
Typical lead-based contrast agents do not exhibit optimal X-ray absorption properties when used with X-ray tube potentials below
90 kilo-electron volts (keV).Wehave developed a high-atomic number lanthanide (erbium) contrast agent, with aK-edge at 57.5 keV.
This approach optimizes X-ray absorption in the output spectral band of conventional microfocal spot X-ray tubes. Erbium oxide
nanoparticles (nominal diameter < 50 nm) suspended in a two-part silicone elastomer produce a perfusable fluid with viscosity of
19.2mPa-s. Ultrasonic cavitationwas used to reduce aggregate sizes to<70 nm. Postmortem intactmice were perfused to investigate
the efficacy of contrast agent.The observed vessel contrast was>4000Hounsfield units, and perfusion of vessels< 10 𝜇m in diameter
was demonstrated in kidney glomeruli. The described new contrast agent facilitated the visualization and quantification of vessel
density and microarchitecture, even adjacent to dense bone. Erbium’s K-edge makes this contrast agent ideally suited for both
single- and dual-energymicro-CT, expanding potential preclinical research applications inmodels of musculoskeletal, oncological,
cardiovascular, and neurovascular diseases.
1. Introduction
It is increasingly important in preclinical research to study
the vasculature in both soft tissue and bone [1–5]. This
includes visualization, quantification, and characterization of
microvessels (i.e., vessels less than 10𝜇m in diameter).Micro-
computed tomography (micro-CT) can provide images with
spatial resolution better than 5 𝜇m in both intact specimens
and in ex vivo small animals [6–8]. However, blood-filled
vessels lack inherent radiographic contrast, requiring the
use of an exogenous contrast agent that can pass through
capillaries and be retained within the vascular system. The
increased contrast provided by such an agent facilitates auto-
mated (or semi-automated) segmentation (i.e., separation) of
the perfused vasculature from surrounding tissues.
The performance (sensitivity, specificity, and accuracy)
of vessel segmentation algorithms has been shown to be
dependent on the signal-to-noise ratio (SNR, defined as the
ratio of the vessel signal to background noise) between the
contrast-enhanced vasculature and surrounding tissue in the
micro-CT image [9]. Higher SNR results in a more robust
and objective classification of the perfused vessels, leading to
a more accurate assessment of their microarchitecture. The
SNR can be increased by either reducing background noise
or increasing the signal intensity within the vessel. However,
decreasing micro-CT image noise is typically impractical, as
it is achieved throughmuch longer scan times [10].Therefore,
the most effective method to increase vessel SNR is to
increase the contrast within the vasculature, using a radio-
paque exogenous contrast agent.
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Several formulations of exogenous vascular contrast
agents are commonly available. Most clinical contrast agents
for in vivo use are iodine-based; however, their small molec-
ular size of <800Da results in rapid clearance (i.e., within
minutes) via the kidneys [11, 12]. Even in postmortem studies
with increased iodine concentrations and scan times, the
short retention time of these iodine-based agentsmakes them
unsuitable for microvessel studies. Preclinical exogenous
agents, of larger molecular sizes (i.e., >1100Da), can remain
within the blood pool for hours [13, 14].These contrast agents
are typically iodine-, barium-, or lead-based and have been
used effectively to study vessel microarchitecture in the heart
[15, 16], kidney [17, 18], tumours [19, 20], nerves [21–23],
and long bones [24, 25]. However, these preclinical contrast
agents do not exhibit optimal X-ray absorption (and hence
do not optimize SNR) on a large installed base of micro-CT
machines that typically operate at a maximum of 90 kilo-
electron volts (keV).
X-ray absorption, responsible for observed contrast
within X-ray images, is influenced by the K-edge of the con-
trast material (i.e., the energy required to eject an inner K-
shell electron). The K-edges for common preclinical contrast
agents are 33 keV for iodine, 37.4 keV for barium, and 88 keV
for lead. These K-edge energies are not optimally matched
for typical micro-focus tubes operating at a peak potential
of 90 kVp, as the K-edge energies are located either at the
low- or high-energy range of the output spectrum of the tube.
Ideally, a contrast agent with a K-edge closer to the mean
energy of the output spectrum of these micro-CT machines
(i.e., ∼50 keV) would provide enhanced X-ray absorption.
The lanthanide erbium (Er), with a K-edge at 57.5 keV,
would provide the contrast necessary for micro-CT scanners
operating at 90 kVp. An Er-based contrast agent would also
provide an additional benefit for dual-energy micro-CT
studies, which require CT scans above and below the K-edge
of the material of interest [26]. In this study, we describe a










nanoparticles form a colloidal suspension
in a continuous-phase fluid (i.e., two-part liquid silicone
elastomer). This methodology of contrast agent fabrication
resulted in a high-atomic number (and consequently highly
X-ray attenuating) ex vivo vascular perfusion contrast agent,
with sufficiently low viscosity (19.2mPa⋅s) to ensure the per-
fusion of the microvascular network (<10 𝜇m).
Using micro-CT, we demonstrate the efficacy of the
custom contrast agent in a postmortem murine model. The
contrast agent perfused the smallest vessels (i.e., capillaries)
and provided increased SNR, facilitating the visualization of
microvessels with diameter < 10 𝜇m. The Er-based contrast
agent provided a greater SNR than commercially available
agents, while also possessing a more appropriate absorption
K-edge energy (57.5 keV). The resulting increase in vessel
contrast would enhance the performance and automation of
segmentation algorithms in all types of vascular networks
and small-animal models (for both single- and dual-energy
studies). This approach will be applicable in many preclinical
studies, includingmusculoskeletal, cardiovascular, neurovas-
cular, and oncological research programs.
2. Materials and Methods





) nanoparticles (NPs) were chosen as the main con-
stituent of the contrast agent, due to their high X-ray attenu-
ation and availability in a nanoparticulate powder (nominal





vascular network, a commercially available two-part silicone
elastomer (commonly used for vascular perfusion, Microfil
MV-132, Flowtech Inc., Carver, MA, USA) was chosen as
the carrier matrix. Uncured, this silicone elastomer has a
manufacturer-reported viscosity of 20mPa⋅s andwhen cured,





form a stable silicone cast of the perfused vasculature. Initial




NPswithin the two-part silicone elastomer. Analysis, via con-





revealed the tendency of the NPs to naturally aggregate into
clusters > 1 𝜇m, due to van derWaals forces—nanoparticulate
powders have been shown to naturally clump and formmuch
larger particle sizes when left uncoated or untreated [27, 28].
Large aggregates such as these could clump together and
prevent the perfusion of arterioles and capillaries, inhibiting
perfusion of the venous system.Thus, to address the fact that
uncoated nanoparticles tend to aggregate into large clumps





NPs in the final product remained smaller than










NPs of ∼50 nm nominal diameter (Nanostructured
and Amorphous Materials, Houston, TX, USA) were ground
using a mortar and pestle for ∼5 minutes to break down
large aggregates. The ground powder was then mixed with
an additive-free clear two-part silicone elastomer (Microfil
MV-132, Carver, MA, USA), which is mixed in a ratio of
two-part MV-Diluent to one-part MV-132. To prepare 30mL





was added to 17.47mL of MV-Diluent and 8.73mL of MV-
132; the remaining 3.8mL was comprised of the curing
agent described below, which was added immediately prior





powder and silicone elastomer was probe sonicated
(BransonDigital Sonifier 450D, standard 13mm tapped horn,
Crystal Electronics, Newmarket, ON,Canada) for a total of 35
minutes with 25% amplitude and a duty cycle of 30 s ON to
10 sOFF. Due to the intense heat generated during sonication,
the samples were immersed in an ice bath and sonication was





NP silicone elastomer suspen-
sion was prepared several hours prior to perfusion, to allow
particle aggregates to settle, and then decanted prior to use. If
prepared further in advance, sonication of the suspension of
5–10 minutes is required to ensure particle resuspension.
2.1.2. Curing Agent. To facilitate consistent and controlled




NP silicone elastomer suspension, a
tin-based curing agent was prepared in-house. The curing
agent comprised a solution of 40% (w/w) dibutyltin dilaurate
Contrast Media & Molecular Imaging 3
(SigmaAldrich, St. Louis,MI,USA) in tetraethyl orthosilicate
(Sigma Aldrich, St. Louis, MI, USA), which was mixed using
a magnetic stirrer for several hours until it became a homo-
geneous pale-yellow transparent solution.
2.2. Er-Based Contrast Agent Characterization. Particle and





evaluated visually using confocal fluorescence microscopy.





the two-part silicone elastomer were dispensed on a glass
bottom microwell dish (MatTek Corporation, Ashland, MA,
USA). Following sonication, drops of the prepared Er-based
suspensionwere placed on a separatemicrowell dish. Samples
were analyzed using confocal fluorescencemicroscopy (Leica
DMi8, Wetzlar, Germany), an Ar 488 nm laser for excitation,
and emission bandwidths of 493–739 nm. To visualize parti-
cle sizes within the nonsonicated “raw” sample and sonicated
suspension, a 20x (HC PL APO CS2 20x/0.75 DRY) and 63x
(HC PL APO CS2 63x/1.40 OIL) objective lens were used,
respectively.
Dynamic light scattering (DLS) was used to quantify the
size distribution of the prepared Er-based suspension. A 10%
(v/v) dilution of the suspension in MV-Diluent was prepared
and analyzedwithDLS (ZetaSizerNano Instrument,Malvern
Instruments Ltd., Malvern, UK). Measurements were per-
formed at room temperature (25∘C) in a quartz cuvette
(1mg/mL).
The viscosity of the contrast agent was measured using a
lab-based Modular Compact Rheometer (MCR 302, Anton
Paar, Graz, Austria); the measured viscosity was used to
correct the DLS measurements.
2.3. Animals. All animal studies were approved by the
Animal Use Subcommittee at Western University (protocol
#2015-018). Five male C57BL/6 mice (∼30 g) were used for
this study.The mouse model was selected to demonstrate the




contrast agent to perfuse the micro-
vasculature of the smallest of the commonly used small-
animal models. Anesthetized mice were first exsanguinated
with sterile saline followed by perfusion with the Er contrast
agent. To prevent blood clot formation during exsanguina-
tion, sterile 0.9% (w/v) saline was heparinized to 0.4% (1mL
of heparin (Sandoz, QC, Canada) in 250mL saline). Sterile
tubing (Baxter Canada, Mississauga, ON, Canada), 1.8m in
length, was used to connect the saline bag to a blunted 21G
× 3/4󸀠󸀠 butterfly catheter (BD, Franklin Lakes, NJ, USA).
The saline IV bag was hung 127 cm above the surgery table,
thereby providing a pressure of 94mmHg. Five minutes
prior to the start of the procedure the mice were given a
100 𝜇l intraperitoneal injection of heparin. After induction of
anesthesia (3% isoflurane (Baxter Canada, Mississauga, ON,
Canada) in O
2
at a rate of 2mL/min) an incision was made
along the thoracic cavity exposing the heart. The butterfly
catheter was carefully inserted into the left ventricle parallel
to the septum. A drop of cyanoacrylate (Krazy Glue, Elmer’s
Products, Atlanta, GA, USA) was applied at the entry point
of the catheter into the left ventricle to avoid accidental
piercing of the septum. The right atrium was clipped to
allow for circulatory system drainage. The heparinized saline
solution was perfused throughout the circulatory system for
10 minutes to ensure complete removal of the blood.
During saline perfusion, 3.8mL (12.7% v/v) of curing





suspension and vortexed (VWR Fixed Speed Vortex Mixer,
Radnor, PA, USA) continuously for 8 minutes. The contrast
agent was injected into an empty IV bag (with separate
1.8m of surgical tubing) and hung 160 cm above the mice
(129mmHg). While this value is greater than the mean
arterial pressure (MAP) of mice (∼103mmHg) [29, 30], it
was chosen to ensure complete perfusion of the animal before
the contrast agent cured. Furthermore, the perfusion pressure
used in this study is significantly lower than the >150mmHg
used in prior studies using the lead-based Microfil agent
[22, 31–33]. Perfusion at a pressure more closely matched to
peak systolic pressure (i.e., ∼120mmHg) reduces the risk of
vascular dilation and capillary rupture. The contrast agent
was let to freely perfuse through the animal until completely
cured, which occurred approximately ∼35 minutes after start
of perfusion. Following contrast agent curing, mice were
placed in 10% neutral buffered formalin overnight, prior to
micro-CT scanning.
2.4. Data Collection and Analysis. Whole body mouse scans
were acquired with a preclinical micro-CT scanner (Vision
120, GEHealthcare, London, ON, Canada).The scan parame-
ters were 90 kVp (no added filtration), 40mA, 900 views, 0.4∘
increment angle over 360∘, geometric magnification of 1.13,
and 16ms exposure, resulting in a total exposure time of 14.4 s
and 576mAs. Including the time required for gantry motion
and recording of image projections, the total acquisition time
was 5 minutes.The projection images were binned 2 × 2 prior
to reconstruction for a final isotropic voxel spacing of 100 𝜇m.
Higher resolution scans of the hindlimb regions were
acquired on a specimen scanner (Locus, GE Healthcare,
London, ON, Canada) using a 3 hr scan protocol (900 views,
80 kVp, 80 𝜇A, no added filtration, 0.4∘ increment angle over
360∘, geometric magnification of 1.41, 15-frame averaging,
and 2× 2 binning for a final isotropic voxel spacing of 40 𝜇m).
To prevent sample motion during these high-resolution
image acquisitions, the perfusedmousewas placed in a 50mL
tube.
Confirmation of perfusion of microvessels (i.e., <10 𝜇m)
was achieved by high-resolution micro-CT. Fabricated
microvessel constructs or synthetic capillaries have been
utilized to evaluatemicrovessel perfusions in the past [34, 35],
but fabricating synthetic vessels with diameters on the order
of 10 𝜇m remains technically challenging. Fortunately, the
mouse kidney is a well-characterized organ system, with
known vessel diameters ranging from the renal artery (∼
0.3mm) to capillaries (∼10 𝜇m) [36, 37]. The kidney contains
many glomeruli (responsible for the waste removal and blood
filtering), which are comprised of capillaries in a bundle of





kidney was embedded in paraffin in a 1.2mL tube (Corning,
Corning, NY, USA) and scanned with a specimen scanner
(Locus SP, GE Healthcare, London, ON, Canada), using a
16 hr protocol. Scan parameters were 80 kVp, 80 𝜇A, 900 pro-
jections, no added filtration, 0.4∘ increment angle over 360∘,









powder naturally aggregated to largemicrosized (>10𝜇m)
particles when mixed within the two-part silicone elastomer, making the suspension not suitable for microvascular perfusion. However, with
sonication, nanosized (∼70 nm) particles were achieved (b).
geometric magnification of 3.83, 14-frame averaging, and 1 ×
1 binning for a final isotropic spatial resolution of 4.8𝜇m.
The micro-CT scanners used in this study were all
equipped with a CsI-based energy-weighted detector. It has
been shown that the peak response of these detectors [39] is
very close to the absorption K-edge of Er (57.5 keV), making
them ideally suited for detection of an erbium-based contrast
agent.
Each of the scans contained calibrators of water and
air, which were used for image calibration and conversion
into Hounsfield units (HU). This allowed us to quantify the
amount of contrast enhancement of perfused vasculature,
based on the the CT signal level in HU within various organs
throughout the vascular system. Using 3D visualization and
analysis software (MicroView, GE Healthcare, London, ON,
Canada), regions of interest (ROI) 500 × 500 × 500 𝜇m were
generated in each region and the mean HU values recorded.
Specifically, for all mice, the mean HU was determined from
the heart (left ventricle), testes, and inferior vena cava (IVC),
as they represented the beginning, middle, and end of the
perfusion pathway, respectively. The CT signal levels within
the selected organs were compared to cortical bone within
the diaphysis region (i.e., the densest endogenous contrast)
and a commercially available lead-based contrast agent. A
rat hindlimb previously perfused with the widely used and
commercially available lead-based contrast agent (Microfil
MV-122, Flowtech Inc., Caver, MA, USA) was scanned using
the 100 𝜇m acquisition protocol.
All statistical analyses were performed using Prism 6
(GraphPad Software Inc., La Jolla, CA, USA). Repeated
measures ANOVA was used to test for statistical differences
between all Er-based contrast-enhanced regions (i.e., heart,
testes, and IVC) and cortical bone. In a separate test, one-
way unpaired ANOVA was performed to compare the mean
attenuation in Er-perfused vessels against cortical bone and
the Microfil MV122-perfused rat femoral artery. Statistical
differences were noted if a 𝑝 < 0.05 was achieved.
3. Results
3.1. Efficacy of an Ex Vivo Er-Based Contrast Agent for
Vascular Perfusion. An effective preclinical postmortem X-
ray compatible vascular contrast agent must be comprised of
small, X-ray attenuating particles homogeneously suspended
within a low viscosity medium. These characteristics will
ensure uniform contrast enhancement of perfused vascu-
lature, including microvessels with diameter < 10 𝜇m (i.e.,
capillaries). Automated segmentation algorithms, which are
typically based on grey-scale levels, require homogeneous
perfusion of microvessels to effectively separate perfused
vasculature from surrounding tissues, so it is essential to
employ an appropriate particle size, uniformly distributed in
the carrier medium.
Ultrasonic cavitation (sonication) was used to success-





gates, which could be homogeneously incorporated within
the two-part silicone matrix. Following intense sonication, a










were found to remain in suspension for several days, allowing
for the contrast agent to be prepared several days prior to use.
Confocal fluorescence microscopy visually confirmed that





trast agent suspension (Figure 1(b)) was less than 100 nm—a
size that can pass easily through the microvessels of any
vascular system.
The ability of a contrast agent to perfuse the microvascu-
lature also depends on its viscosity. Measuring the viscos-
ity of the uncured Er-based contrast agent—at 19.2mPa⋅s—
demonstrated agreementwith the 20mPa⋅s viscosity reported
by the manufacturer of the two-part silicone elastomer, con-




contrast agent is able to pass
through small vessels under standard perfusion pressures.
Based on the measured viscosity of 19.2mPa⋅s, the DLS
measurement reported a Gaussian particle size distribution
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Figure 2: Dynamic light scattering (DLS) results demonstrating the





Average particle size is 72.2 ± 2.2 nm. Results of a suspension that
was mixed and subsequently stored for 2 years are shown in S1.
with mean hydrodynamic diameter of 64.8 nm, standard
deviation of 11.1 nm, and a range from 44 to 122 nm (Figures
2 and S1; see Supplementary Material available online at
https://doi.org/10.1155/2017/7368384). Measurements of par-





suspension should easily pass through microvessels;
this aspect of performance was further evaluated by micro-





-perfused C57Bl/6 mice scanned with
50 𝜇m isotropic voxel spacing, and rebinned 2 × 2 to a final
resolution of 100 𝜇m, revealed a uniform and homogeneous




contrast agent within the
vasculature throughout the entire perfusedmouse (Figure 3).
The vasculature displayed enhanced contrast in comparison
to surrounding tissues throughout an intact animal; impor-
tantly the attenuation of the contrasted vessels was higher
than that of bone.
Scans of Er contrast-perfused hindlimbs were acquired
with 20𝜇m isotropic voxel spacing and subsequently re-
binned 2 × 2 for a final resolution of 40 𝜇m (Figure 4),
to observe the smaller vasculature next to the dense bony
structures of the femur and tibia. From these results, we
were able to clearly see a feeding artery that runs within
(Figure 4(a)) and along (Figure 4(b)) the entire length of
each long bone. At this higher resolution, smaller structures
such as a foramen (i.e., an opening for blood vessels to
enter bone) can be visualized (Figure 4(c)). The ability to
differentiate the foramen from the vessel running through it
is particularly noteworthy, as this is not possible with other
contrast agents that have lower attenuation coefficients. The
observed perfusion of the venous system (Figure 4(a) yellow
arrows) suggests successful perfusion of the capillaries, which
is further supported by the lack of visible contrast agent
poolingwithin the interstitial space (poolingmight have been
observed if overpressurization during perfusion had caused
microvessel rupture).
3.2. Visualization of Capillary Bed Perfusion. The results of




contrast agent successfully perfused the entire continuous,
well-ordered vascular tree of the kidney (Figure 5). The con-
trast enhancement of the vasculature was sufficiently high,
such that a single grey-scale threshold separated perfused
vasculature from surrounding tissues, allowing for the gen-
eration of 3D images of the kidney vessel microarchitecture




vascular “cast” (Figures 5(a)
and 5(b)) showed complete perfusion from the abdominal
aorta (i.e., the main feeding vessel) down to the 6th and 7th
arterial branches (i.e., glomeruli afferent arterioles). Previous
research has shown that mouse glomeruli afferent arterioles
can be as small as ∼13 𝜇m [36]; thus, visualization of indi-
vidual glomeruli (i.e., several capillaries) suggests that our
contrast agent is able to perfuse structures < 13 𝜇m (Figures
5(c) and 5(d)). While previous research has shown perfusion
of the kidney down to the afferent arterioles [36, 40–42] using
a commercially available lead-based contrast agent, the main




-based contrast agent is its ability to
provide higher contrast and SNR.
3.3. Contrast Enhancement Provided by the Er-Based Contrast
Agent in Micro-CT. The measured mean CT values for the
heart (4094 ± 264HU), testes (4107 ± 182HU), and IVC
(4001 ± 305HU), compared in Figure 6, showed no signifi-
cance difference (𝑝 = 0.3940) between these three regions.
On the other hand, the mean signal from cortical bone
(2359 ± 207HU) and the lead-based contrast agent Microfil
MV-122 (2683 ± 77.6HU) were significantly lower than the
signal from the Er contrast-agent perfused vasculature (𝑝 <
0.006 and 𝑝 < 0.0001 for bone and Microfil, respectively).
The approximately 1400HU difference in signal between that




-based contrast agent and cortical
bone will aid in facilitating the automatic segmentation of
vessels from surrounding bone, which is not possible when
commercially available contrast agents, such as Microfil MV
122, are used.
4. Discussion





nanoparticles within a two-part
silicone elastomer, forming a colloidal suspension capable
of providing high X-ray attenuation that can facilitate the
visualization and characterization of microvessels within a
small-animal model. In this study, we characterized and
investigated the capabilities of the custom ex vivo Er-based
vascular perfusion contrast agent.





aggregates (i.e., >100 𝜇m) into nm-
sized particles (Figures 1(b) and 2) suspended within a
silicone carrier. The prepared suspension was determined to
possess low viscosity and a narrow particle size distribution
that would facilitate the perfusion of intact whole body mice
(Figure 3). Micro-CT scans acquired with both 50 and 20 𝜇m
isotropic voxel spacings revealedwhole-mouse perfusion and
higher-ordered vascular branching (i.e., 1st to 3rd order)
and visualization of vessels within bone (Figures 3 and 4).
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Figure 3: Rebinned 100 𝜇m voxel images where the (a) maximum intensity projection (MIP) of a whole body perfused mouse demonstrates




contrast agent in the vasculature is higher than the mouse’s skeletal structure. Quantitative measurements







Figure 4: Multiplanar reformatted images at 40 𝜇m, resulting from 2 × 2 rebinning of 20 𝜇m acquired micro-CT scans, clearly depict the
ability to visualize the extent of the nutrient arteries, which run along the tibia and femur. Red arrows highlight the nutrient arteries in cross-
section in (a) and along their entire length in (b). At this resolution the depiction of parallel arteries and veins (yellow arrows) indicates
successful perfusion through the capillary network. The ability to visualize vessels as they pass through a foramen (green arrows) into bone
is depicted in (c).
Contrast Media & Molecular Imaging 7




Figure 5: (a)MIP of an entire mouse kidney and attached adrenal gland (arrow) perfused with the new Er contrast agent. (b) 3D rendering of
the perfused kidney with a plane cut to demonstrate an entire intact vascular tree. (c) Magnified 0.35mm thick slice MIP of the area outlined
in red in (a), demonstrating 6-7th level arterial branching. (d) 3D rendering of the terminal arteriole branches, ending in the glomeruli (the
kidney’s spherical capillary bed). G: glomeruli; AF: afferent arteriole; EF: efferent arteriole; RA: cruciate radial artery; RV: cruciate radial vein;
AA: arcuate artery; AV: arcuate vein; and VR: vasa recta.
High-resolution scans with 5 𝜇m spatial resolution demon-
strated well-characterized vascular microarchitecture within
a perfused kidney, with observed vascular filling down to
vessels <13 𝜇m in diameter and contrast enhancement of
capillary beds (i.e., glomeruli, Figure 5). Additionally, the
attenuation of the Er-based contrast agent was found to be
significantly higher than that of cortical bone (i.e., the dens-
est naturally occurring substance within our samples) and
the commonly used lead-based Microfil (MV-122) vascular
contrast agent (Figure 6). This study clearly demonstrates
the efficacy of the custom Er-based suspension as an ex vivo
micro-CT vascular perfusion contrast agent.
An important benefit of the presented Er-based contrast
agent is an X-ray attenuation coefficient that is significantly
higher than that of both bone and other existing contrast
agents. This difference facilitates the separation of microves-
sels from both soft tissue and bone in the images and can also
result in a reduction of scan time. While shorter scans result
in a greater amount of noise [10], the higher contrast between
the Er contrast agent within the vasculature and surround-
ing tissue ensures that SNR remains high despite the shorter
scan times.The approach used to incorporate the Er nanopar-
ticles within the suspension (i.e., ultrasonic cavitation) ren-
ders the approach amenable to the production of custom
contrast agents of varying elemental compositions and con-
centrations. Furthermore, silicone-compatible colorants can
also be introduced within the silicone media to allow for
the customization of the contrast agents’ visual appearance
against tissue; this may be useful for macroscopic visualiza-
tion and postmortem histological analysis.
In the current implementation, each working volume of
contrast agent (i.e., 30ml) is prepared individually, requiring
approximately one hour of operator time. Larger volumes
of contrast agent could be prepared in advance, with the

















Figure 6: Heart, testes, and inferior vena cava (IVC) were chosen
to represent the start, middle, and end of the perfusion route. The




-based contrast agent in all three
regions was significantly higher than that of cortical bone (𝑝 <





-enhanced vasculature was significantly higher than
that commercially available lead-based Microfil MV122 (one-way
ANOVA, 𝑝 < 0.0001), while there was no difference between
Microfil MV122 and cortical bone (𝑝 > 0.9999).
curing catalyst being added just prior to usage. In this case,
additional sonicationmay be required to ensure resuspension
of aggregated particles (Figure S1).
As with other cast-forming contrast agents (e.g., Microfil)
the new Er-based contrast agent is limited to applications
of postmortem vascular analysis at study endpoints. This
limitation requires that larger cohorts of animals are needed
to assess changes to the vasculature over periods of time.
An in vivo contrast agent would make investigations with
reduced sample size possible and allow for the study of
vascular changes within the same animal over time; however,
development of an in vivo contrast agent is not within the
scope of this study. Currently, there exist in vivo contrast
agents that reside within the blood pool for extended periods
of time [43, 44]; thus, we expect that the incorporation of Er
into an in vivo agent is possible.
5. Conclusions
We have demonstrated the effectiveness of an Er-based sus-
pension as a single-energy X-ray vascular contrast agent
that significantly enhances the contrast—in comparison to
surrounding dense bone and commercially available lead-
based contrast agents (Figure 6)—of perfused vasculature
within small animals (Figures 3–5). With an absorption K-
edge at 57.5 keV, the Er-based contrast agent is also ideally
suited for dual-energymicro-computed tomography (DECT)
on a large installed base of high-resolution preclinical micro-





-based vascular perfusion contrast agent with opti-
mized DECT scan protocols and spectral shaping (using X-
ray filtration) would facilitate rapid and automatic quantita-
tive segmentation of perfused vasculature from surrounding
tissues [26], a process that is otherwise difficult due to partial
volume effects that can limit traditional single-energy CT
scans. Dual-energy CT-based material separation has been
shown to be beneficial in studying a range of diseases in
clinical applications (i.e., gout, cardiovascular, and cancer)
[45–47], by allowing for the quantitative separation of the
material of interest from surrounding tissues. The novel con-
trast agent that we describe has the potential to provide these
advantages of DECT-based quantification and segmentation
for preclinical investigations of vascular changes in small-
animal models.
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